Investigators employed the Accelerating Medicines Partnership to identify noninvasive biomarkers of lupus nephritis pathology and treatment response.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback